Other cohort studies on cancer patients with CD26 inhibitor intake have shown a better long-term outcome in colorectal (7) or prostate cancers (8), while patients with pancreatic or breast cancer did not have this favorable effect (8). This evidence concerns the gene DPP4 and prostate carcinoma.